Current Treatment Patterns Among Postmenopausal Women with HR+/HER2− Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
- 26 March 2018
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 35 (4) , 482-493
Abstract
Recent approval of novel agents has changed the treatment landscape for post menopausal women with hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2−) metastatic breast cancer (mBC). The objective of this study was to describe contemporary treatment patterns among postmenopausal women with HR+/HER2− mBC in the real-world setting.Keywords
Funding Information
- Novartis Pharmaceuticals Corporation
This publication has 12 references indexed in Scilit:
- The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast CancerCurrent Treatment Options in Oncology, 2017
- Palbociclib and Letrozole in Advanced Breast CancerNew England Journal of Medicine, 2016
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerNew England Journal of Medicine, 2016
- Clinical and economic outcomes by first-line treatment among women with HR+/HER2– metastatic breast cancer in a large US health plan databaseCurrent Medical Research and Opinion, 2016
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialThe Lancet Oncology, 2016
- Palbociclib in Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2015
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyThe Lancet Oncology, 2015
- Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumorsSpringerPlus, 2014
- Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2−) breast cancer patients in the United States: 2002–2012Current Medical Research and Opinion, 2014
- Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancerCurrent Medical Research and Opinion, 2014